Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Executive Summary

• Zero Candida Technologies, Inc. officially announced the grant of Patent No. 12654025B2, marking a significant milestone in its development of next-generation FemTech medical devices.
• The patent covers the ZC-001, a smart, AI-enabled therapeutic device designed for the at-home treatment of Vulvovaginal Candidiasis (VVC) using precision blue light therapy, targeted drug delivery, and wireless diagnostics.
• The technology is positioned to integrate advanced AI capabilities for disease detection, direct physician reporting, and automated pharmacy ordering, targeting a VVC treatment market projected to exceed US $2B by 2030.

Key Details

• Patent Number: 12654025B2
• Device Name: ZC-001
• Core Technology: Integrates precision blue light therapy, targeted drug delivery, and wireless diagnostics for personalized at-home care.
• Target Indication: Vulvovaginal Candidiasis (VVC), with a specific focus on recurrent (four or more episodes per year) and drug-resistant infections.
• AI & Connectivity Features: Designed to evolve with AI capabilities to treat fungal infections, detect new diseases, report diagnostic data directly to physicians, and automatically order medication from pharmacies.
• Clinical & Operational Rationale: Aims to improve patient outcomes, reduce the need for repeated in-clinic visits, and address a condition affecting approximately 75% of women globally.
• Market Projection: The VVC treatment market is projected to exceed US $2 billion by 2030.
• Company Tickers: TSXV: ZCT, OTCQB: ZCTFF, FSE: 9L2